1. Protein Tyrosine Kinase/RTK
  2. PDGFR

PDGFR

PDGFR (Platelet-derived growth factor receptors) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGFR: PDGFR alpha and PDGFR beta.

PDGFR Isoform Specific Products:

  • PDGFR

  • PDGFRβ

  • PDGFRα

PDGFR Related Products (55):

Cat. No. Product Name Effect Purity
  • HY-10201
    Sorafenib Inhibitor 99.83%
    Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-10331
    Regorafenib Inhibitor 99.95%
    Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
  • HY-10201A
    Sorafenib Tosylate Inhibitor 99.73%
    Sorafenib tosylate is a potent multikinase inhibitor, with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-12047
    Ponatinib Inhibitor 98.96%
    Ponatinib is a potent, orally available multi-targeted kinase inhibitor with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
  • HY-10255A
    Sunitinib Inhibitor 99.66%
    Sunitinib is a potent tyrosine kinase inhibitor targeting VEGFR2 and PDGFRβ with IC50 of 80 nM and 2 nM, respectively.
  • HY-112306
    DCC-2618 Inhibitor
    DCC-2618 is a pan-KIT and PDGFRA inhibitor, and has antitumor activity.
  • HY-100315
    Tyrosine kinase-IN-1 Inhibitor
    Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively.
  • HY-50904
    BIBF 1120 Inhibitor 99.75%
    BIBF 1120 is a potent triple angiokinase inhibitor for VEGFR1/2/3FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
  • HY-15463
    Imatinib Inhibitor 99.80%
    Imatinib is a known inhibitor of the c-Kit, Bcr-Abl, and PDGFR tyrosine kinases, inhibits the SLF-dependent activation of c-Kitwt kinase with IC50 of ~100 nM, which is similar to the concentration requires for inhibition of Bcr-Abl and PDGFR.
  • HY-50946
    Imatinib Mesylate Inhibitor 99.90%
    Imatinib Mesylate is a known inhibitor of the c-Kit, Bcr-Abl, and PDGFR tyrosine kinases, inhibits the SLF-dependent activation of c-Kitwt kinase with IC50 of ~100 nM, which is similar to the concentration requires for inhibition of Bcr-Abl and PDGFR.
  • HY-10255
    Sunitinib Malate Inhibitor 99.47%
    Sunitinib Malate is a potent tyrosine kinase inhibitor targeting VEGFR2 and PDGFRβ with IC50 of 80 nM and 2 nM, respectively.
  • HY-13223
    Crenolanib Inhibitor 99.78%
    Crenolanib is a potent and selective inhibitor of PDGFRα/β, FLT3 with Kd of 2.1 nM/3.2 nM, 0.74 nM, respectively, sensitive to D842V mutation not V561D mutation, and > 100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src.
  • HY-10208
    Pazopanib Inhibitor 99.16%
    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
  • HY-10065
    Axitinib Inhibitor 99.77%
    Axitinib is a receptor kinase inhibitor of VEGFRs and, at higher doses, PDGFRs (IC50=0.1 nM for VEGFR1, 0.2 nM for VEGFR2, 0.1-0.3 nM for VEGFR3, and 1.6 nM for PDGFRβ).
  • HY-10407
    SU 5402 Inhibitor 99.23%
    SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.
  • HY-50751
    Linifanib Inhibitor 99.42%
    Linifanib (ABT-869) is a multi-targeted inhibitor of VEGF and PDGFR receptor family with IC50s of 3, 4, 66, 4 nM for KDR, Flt-1, PDGFRβ and FLT3.
  • HY-50905
    Dovitinib Inhibitor 99.31%
    Dovitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.
  • HY-10209
    Masitinib Inhibitor 99.70%
    Masitinib is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, and has weak inhibition to ABL and c-Fms.
  • HY-10205
    Cediranib Inhibitor 99.58%
    Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
  • HY-10501
    SU14813 Inhibitor
    SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.